Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression

Abstract

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard treatments for advanced non-small-cell lung cancer (NSCLC) patients. However, acquired resistance to EGFR-TKIs is widely detected across the world, and the exact mechanisms have not been fully demonstrated until now. This study aimed to examine the role of miR-214 in the… (More)
DOI: 10.1038/s41598-017-00901-6

Topics

6 Figures and Tables

Cite this paper

@inproceedings{Liao2017DownregulationOM, title={Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression}, author={Jinrong Liao and Jinghui Lin and Dong Jun Lin and Changyan Zou and Jessica S. Kurata and Renjang Lin and ZhiYong He and Ying Su}, booktitle={Scientific reports}, year={2017} }